Some Biomarkers in Bronchial Asthma in Children

• Conditions: Bronchial Asthma
• Interventions: Diagnostic Test: asymmetric dimethylarginine

• Registration Number: NCT04175093
• Lead Sponsor: Assiut University

Brief Summary

Asthma, a disease characterized by chronic airway inflammation and hyper -responsiveness, is a common disease that affects all age groups. Asthma may be manifested as irreversible airflow obstruction in some patients. Although the pathogenesis of asthma is not well understood, increased oxidative stress due to an imbalance of oxidants and antioxidants has been found to be associated with asthma. In asthma, inflammation-related oxidative stress is driven by exposure to a variety of triggers, including allergens and viruses, which activate components of both the innate and acquired immune responses. Protection by escaping from triggering factors or standardization of asthma medication is difficult and usually is not enough for effective treatment. On the other hand, correction of antioxidative systems may be more efficacious in the control of asthmatic inflammation and asthma symptoms.

Little is known about the role of asymmetric dimethylarginine in the pathogenesis of asthmatic airway inflammation. The lung is a major source of asymmetric dimethylarginine that can promote oxidative stress by a reduction in nitric oxide synthesis which would result in higher levels of peroxynitrite, that causes oxidative cell damage, and exacerbate airway inflammation. asymmetric dimethylarginine can modify lung function, increase airway hyper-reactivity even in non-inflamed airways, and promote lung collagen production and deposition. Increased asymmetric dimethylarginine in serum has been found to be associated with the severity of symptoms of asthma in obese adults.

Malondialdehyde is an oxidant marker of pulmonary oxidative stress, and lipid peroxidation. Paraoxonase, an antioxidant enzyme may play a protective role in asthma. It hydrolyzes lipid peroxides and prevents low-density lipoprotein oxidation.

Detailed Description

Not available

Study Timeline

• Status Verified: 2019-11
• Study First Submitted: 2019-11-20
• Study First Submitted QC: 2019-11-21
• Last Update Submitted: 2019-11-21
• Study First Posted: 2019-11-22
• Last Update Posted: 2019-11-25
• Study Start: 2019-11-29
• Primary Completion: 2020-11-21
• Study Completion: 2021-11-21

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 105

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Mild persistent asthma	asymmetric dimethylarginine	• Group I, patients with mild persistent asthma.
Severe persistent asthma	asymmetric dimethylarginine	• Group III ,patients with severe persistent asthma.
Moderate persistent asthma	asymmetric dimethylarginine	• Group II, patients with moderate persistent asthma.

Primary Outcome Measures

Name	Time	Method
The percentage of asymmetric dimethylarginine in the study groups	24 hours	measurement from serum samples by competitive ELISA with a standard range from 0.1 to 5.0 μmol/L.